Option Care Health, Inc. OPCH
We take great care to ensure that the data presented and summarized in this overview for Option Care Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPCH
View all-
Black Rock Inc. New York, NY21MShares$481 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.2MShares$441 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.92MShares$227 Million0.06% of portfolio
-
Westfield Capital Management CO LP Boston, MA6.49MShares$149 Million0.96% of portfolio
-
State Street Corp Boston, MA6.26MShares$143 Million0.01% of portfolio
-
Thrivent Financial For Lutherans Minneapolis, MN5.86MShares$134 Million0.35% of portfolio
-
Geode Capital Management, LLC Boston, MA4.19MShares$96.1 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.05MShares$92.7 Million0.03% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA3.94MShares$90.4 Million0.49% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.4MShares$77.8 Million0.03% of portfolio
Latest Institutional Activity in OPCH
Top Purchases
Top Sells
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Insider Transactions at OPCH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2024
|
Harry M Jansen Kraemer Jr Director |
BUY
Open market or private purchase
|
Direct |
43,000
+11.64%
|
$946,000
$22.54 P/Share
|
|
Oct 26
2024
|
John Charles Rademacher Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,829
-2.2%
|
$401,041
$29.45 P/Share
|
|
Oct 26
2024
|
John Charles Rademacher Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,216
+4.74%
|
-
|
|
Oct 21
2024
|
Nicole Maggio Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-2.27%
|
$10,260
$30.51 P/Share
|
|
Oct 21
2024
|
Michael Bavaro Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
911
-2.1%
|
$27,330
$30.51 P/Share
|
|
Oct 21
2024
|
Christopher L. Grashoff Chief Growth Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
911
-3.47%
|
$27,330
$30.51 P/Share
|
|
Oct 21
2024
|
Luke Whitworth Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,785
-3.21%
|
$113,550
$30.51 P/Share
|
|
Oct 21
2024
|
Michael H. Shapiro Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,570
-2.86%
|
$227,100
$30.51 P/Share
|
|
Oct 21
2024
|
Michael H. Shapiro Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,088
+6.07%
|
-
|
|
Sep 03
2024
|
R Carter Pate Director |
SELL
Open market or private sale
|
Direct |
1,465
-3.9%
|
$46,880
$32.37 P/Share
|
|
Sep 03
2024
|
R Carter Pate Director |
SELL
Bona fide gift
|
Direct |
67,342
-64.18%
|
-
|
|
Aug 22
2024
|
Michael H. Shapiro Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,217
-8.58%
|
$696,510
$30.95 P/Share
|
|
Aug 22
2024
|
Michael H. Shapiro Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,217
+7.9%
|
$417,906
$18.97 P/Share
|
|
Aug 22
2024
|
Timothy P Sullivan Director |
SELL
Open market or private sale
|
Direct |
47,249
-69.42%
|
$1,417,470
$30.91 P/Share
|
|
Aug 21
2024
|
Elizabeth Quadros Betten Director |
SELL
Open market or private sale
|
Direct |
47,531
-69.02%
|
$1,473,461
$31.09 P/Share
|
|
Aug 15
2024
|
Michael Bavaro Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
5,765
-11.72%
|
$178,715
$31.42 P/Share
|
|
Aug 15
2024
|
Michael Bavaro Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,765
+3.9%
|
$132,595
$23.93 P/Share
|
|
May 19
2024
|
Collin Smyser GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-0.57%
|
$6,902
$29.78 P/Share
|
|
May 19
2024
|
Collin Smyser GC & Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
812
+1.89%
|
-
|
|
May 19
2024
|
Christopher L. Grashoff Chief Growth Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-5.48%
|
$44,138
$29.78 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 535K shares |
|---|---|
| Open market or private purchase | 78K shares |
| Exercise of conversion of derivative security | 92.8K shares |
| Bona fide gift | 73.8K shares |
|---|---|
| Open market or private sale | 127K shares |
| Payment of exercise price or tax liability | 180K shares |